THE BUSINESS OF LONGEVITY – Chapter NineThe £37,000 Question

Following the Patient Money Behind Cell-Free Therapy

There is a moment in every investigation when separate pieces of information suddenly begin to connect.

For this investigation, that moment came when I returned to something I had discovered much earlier.

The price.

During my earlier investigation into Wellbeing International Foundation, a prospective patient enquiry resulted in a proposed Cell-Free Therapy programme carrying a price of approximately £37,000.

In a separate recorded sales conversation examined during this investigation, a figure of approximately $48,000 was discussed.

These are substantial sums of money.

But after investigating Wellbeing's investment activity, corporate structure and scientific programme, the price now raises a much bigger question.

What exactly is the patient paying for?

And perhaps more importantly:

Where does that money go?

The Price Is No Longer Public

There is an important distinction to make immediately.

Wellbeing's current website does not advertise a fixed price for Cell-Free Therapy.

Instead, prospective clients are told that CFT is a premium bespoke therapy and that pricing depends upon the individual treatment plan, number of doses and whether cell banking is included.

Customers are invited to contact the organisation for a personalised quotation.

Therefore, £37,000 should not be presented as Wellbeing's current universal price.

It is the price communicated during the patient enquiry examined as part of this investigation.

That distinction matters.

But it does not make the figure any less interesting.

What Does £37,000 Buy?

According to Wellbeing's current explanation of its process, treatment begins with a blood draw.

White blood cells are isolated.

Those cells are subjected to controlled environmental conditions in a laboratory.

The resulting secretions—the mixture Wellbeing describes as containing extracellular vesicles, growth factors and cytokines—are harvested.

The living cells themselves are removed.

The preparation is tested before eventually being returned to the patient through an intravenous infusion.

Wellbeing also offers cell banking, allowing biological material to be maintained for possible future preparations.

That explains the process.

It does not explain the economics.

How much does laboratory processing cost?

How much goes to the clinical provider?

How much goes toward transportation and storage?

How much represents research expenditure?

How much supports administration?

How much represents profit?

Those figures are not publicly available.

Patient Revenue Funds the Organisation

This is where the investigation becomes particularly interesting.

Wellbeing itself has now publicly acknowledged that patient revenue forms part of its funding model.

In its announcement concerning the 2026 investment round, the organisation stated that historically its activities have been funded through a combination of:

private investment, patient revenue and selective philanthropic engagement.

That single statement connects several parts of this investigation.

Patients are not simply purchasing a service.

Their payments form part of the financial ecosystem supporting the organisation.

There is nothing inherently unusual about this.

Every private healthcare company survives through patient revenue.

But Wellbeing is not simply operating an established medical service.

It is simultaneously developing the scientific evidence surrounding an emerging biological intervention.

That makes the relationship between treatment revenue and research particularly interesting.

Who Is Funding Whom?

Traditionally, experimental medical research follows a recognisable path.

Research is conducted.

Preclinical evidence develops.

Clinical trials begin.

Safety and effectiveness are evaluated.

Regulatory processes follow.

Eventually, successful interventions reach paying patients.

But regenerative medicine has sometimes developed differently.

Commercial treatment can exist alongside continuing scientific investigation.

That creates an unusual economic relationship.

Patients may effectively become customers of an intervention while the evidence supporting that intervention is still developing.

This raises a perfectly legitimate question:

To what extent is patient revenue helping finance the continuing development of the evidence base behind the treatment patients are purchasing?

Wellbeing's own fundraising announcement says capital supports research, documentation, clinical relationships and operating capacity for its patient population.

The precise allocation of patient-derived revenue, however, is not publicly disclosed.

Treatment or Participation?

This distinction deserves careful consideration.

When someone pays £37,000 for a medical intervention, what do they believe they are purchasing?

An established treatment?

An experimental intervention?

A wellness programme?

Access to emerging biotechnology?

Participation in something still being scientifically evaluated?

Those descriptions carry very different expectations.

Wellbeing's current website contains an important disclaimer.

It states that Cell-Free Therapy is not intended to diagnose, treat, cure or prevent any disease.

That is a significant statement.

Yet elsewhere on the same website, Wellbeing discusses regenerative signals, tissue repair, recovery and biological processes in considerably more ambitious language.

The difference between those messages deserves careful attention.

The Sales Conversation

This becomes particularly important when we compare public disclaimers with the actual sales process.

During the earlier investigation, conversations concerning Cell-Free Therapy moved beyond general discussions about wellness and regenerative biology.

Specific health problems were discussed.

Potential benefits were discussed.

Treatment was proposed.

A substantial price followed.

That is where the distinction between marketing, medical advice and commercial sales becomes important.

A website disclaimer is one thing.

What prospective patients are told during private conversations is another.

The next stage of this investigation will therefore increasingly examine not simply what appears on the website, but what happens after someone makes contact.

The Missing Doctor

Another feature of the earlier enquiry deserves renewed attention.

When substantial medical expenditure is being discussed, most patients would reasonably expect a conventional clinical pathway.

Medical history.

Records.

Diagnosis.

Physician assessment.

Discussion of alternative treatments.

Risks.

Contraindications.

Informed consent.

Only then would treatment normally proceed.

The earlier enquiry examined during this investigation raised questions about when—and how—a treating physician entered that process.

That question becomes considerably more important when tens of thousands of pounds are potentially involved.

Who makes the medical decision?

Who decides whether the patient is suitable?

Who assumes clinical responsibility?

And at what point does that happen?

The Laboratory

Then there is Germany.

Wellbeing repeatedly states that its biological preparations are processed through a GMP-certified laboratory in Germany.

GMP—Good Manufacturing Practice—is an important quality standard.

But the public-facing website does not prominently identify the laboratory by name.

That creates another question.

If part of a £37,000 treatment involves specialist pharmaceutical-grade biological processing, prospective patients might reasonably want to know:

Which laboratory performs that work?

What precisely is its certification?

Which regulatory authority oversees it?

What product classification applies to the material?

Who releases each preparation for clinical use?

Those are technical questions.

But when intravenous biological material is being administered to humans, technical questions matter.

More Than Twenty Delivery Locations

Wellbeing currently describes an international network spanning more than twenty delivery locations across the United States, Europe and other regions.

That sounds substantial.

But Wellbeing describes these locations as partner clinics or clinical relationships rather than necessarily facilities owned by the organisation itself.

That distinction matters economically.

If treatment is delivered through independent clinical partners, how is the patient payment divided?

Does Wellbeing charge for biological processing?

Does the clinic charge separately?

Is there a licensing fee?

A referral arrangement?

A revenue share?

A fixed clinical fee?

Again, none of those possibilities should be assumed.

But understanding the commercial relationship between Wellbeing and its delivery network is essential to understanding the economics of Cell-Free Therapy.

Then There Are the Physicians

Wellbeing is not only seeking patients.

Its current website actively recruits physicians.

One section specifically targets established regenerative medicine practices and promotes what it describes as a clear revenue model and projections, alongside marketing and patient-acquisition support.

That is significant.

It demonstrates that Cell-Free Therapy is not simply being developed as a scientific programme.

There is also a commercial model designed to expand through healthcare practitioners.

That does not invalidate the science.

But it reinforces why the business model deserves examination alongside it.

£37,000 Multiplied

This is where the numbers become potentially substantial.

A single treatment at £37,000 represents significant revenue.

Ten patients at that historical quoted level would represent £370,000.

One hundred would represent £3.7 million.

One thousand would represent £37 million.

Those figures are illustrations—not claims about Wellbeing's actual revenue.

We do not currently have sufficient independently verified patient numbers, average selling prices or financial accounts to calculate the organisation's turnover.

That limitation is important.

But it demonstrates why patient numbers, pricing and financial disclosure matter.

Even relatively small numbers of high-value treatments can create a significant business.

The Patient Becomes Part of the Investment Story

This brings us back to Chapter Eight.

Investors are interested in scalability.

Patient revenue demonstrates commercial demand.

Commercial demand can support valuation.

Valuation attracts investment.

Investment funds expansion.

Expansion creates access to more patients.

More patients generate additional revenue.

That is a perfectly conventional commercial cycle.

But in healthcare there is another element.

Evidence.

If patient demand grows faster than independent scientific evidence, commercial success and clinical validation can begin moving at very different speeds.

That is why this investigation keeps returning to the same principle.

Commercial traction is not clinical proof.

The Three Sources of Money

We can now identify three funding streams acknowledged by Wellbeing itself:

Private investment.

Patient revenue.

Selective philanthropic engagement.

Each carries different expectations.

Investors expect returns.

Patients expect value from treatment.

Philanthropic contributors generally expect their money to support a mission.

Understanding how those different sources of money interact is therefore important.

Are they held within the same organisation?

Do they finance different activities?

Does patient revenue subsidise research?

Does investment subsidise treatment infrastructure?

Does philanthropy support scientific work?

There may be perfectly straightforward answers.

They simply are not apparent from the public financial information currently available.

The Question Is Not Whether Wellbeing Makes Money

This distinction is essential.

There is nothing wrong with making money from healthcare.

Pharmaceutical companies make profits.

Private hospitals make profits.

Medical-device manufacturers make profits.

Biotechnology investors expect returns.

The question is not:

Does Wellbeing make money?

The questions are:

How does it make money?

Which entities receive that money?

What proportion comes from patients?

What does it cost to deliver the intervention?

How much is reinvested into research?

And ultimately:

What financial relationship exists between the treatment business and the investment proposition?

Those are considerably more interesting questions.

What We Still Don't Know

After months of investigation, several pieces of the financial picture remain unavailable publicly.

We do not have independently verified figures showing:

• annual patient revenue;

• average treatment price;

• treatment margins;

• laboratory costs;

• clinic revenue-sharing arrangements;

• research expenditure;

• executive remuneration;

• investor returns;

• company profitability;

• consolidated financial accounts.

Without those figures, anyone attempting to value the business externally is working with an incomplete picture.

That does not mean the information does not exist.

Wellbeing explicitly says detailed financial communication is maintained separately for appropriate investor audiences.

It means the information is not available to us publicly.

The £37,000 Question

So we return to where this chapter began.

A prospective patient is presented with an innovative biological intervention.

The science sounds sophisticated.

The testimonials can be compelling.

The process appears personalised.

And then comes the price.

Approximately £37,000 in the enquiry examined during this investigation.

Before spending that amount of money, I would want answers.

Not because I oppose regenerative medicine.

Quite the opposite.

Innovation deserves serious investigation precisely because some of it may eventually transform medicine.

But extraordinary prices and extraordinary scientific possibilities deserve extraordinary transparency.

What am I receiving?

What evidence demonstrates that it works?

Who is medically responsible?

Who manufactures it?

Who regulates it?

Where does my money go?

And what happens if it does not work?

Those are not unreasonable questions.

For £37,000, they may be the most important questions a patient ever asks.

Looking Ahead

The money has now led us somewhere unexpected.

Back to the medicine.

Because before asking whether £37,000 represents value, we need to understand something even more fundamental.

What exactly is inside the infusion?

Wellbeing describes hundreds of growth factors, extracellular vesicles, cytokines and biological signalling molecules.

But what does that actually mean?

What evidence exists for intravenous delivery?

What happens to these biological signals once they enter the bloodstream?

And does the scientific literature support the extraordinary regenerative potential being associated with them?

That is where the investigation goes next.

Chapter Ten: Inside the Infusion

What Is Cell-Free Therapy Actually Putting Into the Body?